[go: up one dir, main page]

BR9911779A - Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia - Google Patents

Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia

Info

Publication number
BR9911779A
BR9911779A BR9911779-7A BR9911779A BR9911779A BR 9911779 A BR9911779 A BR 9911779A BR 9911779 A BR9911779 A BR 9911779A BR 9911779 A BR9911779 A BR 9911779A
Authority
BR
Brazil
Prior art keywords
hyperglycemia
insulin resistance
benzofurans
treatment
benzothiophenes
Prior art date
Application number
BR9911779-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Jay Edward Wrobel
Arlene Joan Dietrich
Madelene Miyoko Antane
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR9911779A publication Critical patent/BR9911779A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
BR9911779-7A 1998-05-12 1999-05-10 Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia BR9911779A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7671298A 1998-05-12 1998-05-12
PCT/US1999/010209 WO1999061435A1 (en) 1998-05-12 1999-05-10 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia

Publications (1)

Publication Number Publication Date
BR9911779A true BR9911779A (pt) 2001-02-06

Family

ID=22133746

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911779-7A BR9911779A (pt) 1998-05-12 1999-05-10 Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia

Country Status (22)

Country Link
EP (1) EP1077969A1 (no)
JP (1) JP2002516321A (no)
KR (1) KR20010043539A (no)
CN (1) CN1308626A (no)
AR (1) AR015294A1 (no)
AU (1) AU756337B2 (no)
BG (1) BG104918A (no)
BR (1) BR9911779A (no)
CA (1) CA2330620A1 (no)
EA (1) EA200001175A1 (no)
EE (1) EE200000653A (no)
HR (1) HRP20000767A2 (no)
HU (1) HUP0101792A3 (no)
ID (1) ID26244A (no)
IL (1) IL139132A0 (no)
NO (1) NO20005677L (no)
PL (1) PL344081A1 (no)
SK (1) SK16992000A3 (no)
TR (1) TR200003333T2 (no)
TW (1) TW510900B (no)
WO (1) WO1999061435A1 (no)
ZA (1) ZA200005961B (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
WO2002018363A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
WO2002026707A1 (en) * 2000-09-26 2002-04-04 Biovitrum Ab Novel compounds
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
US20030022896A1 (en) * 2001-06-07 2003-01-30 Wyeth PTPase inhibitors for improving cardiovascular risk profile
AR034374A1 (es) * 2001-06-07 2004-02-18 Wyeth Corp Combinacion de un inhibidor de ptpasa y un inhibidor de ace
WO2002098410A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination of a ptpase inhibitor and a sulfonylurea agent
US20030013709A1 (en) * 2001-06-07 2003-01-16 Wyeth Combination of a PTPase inhibitor and an alpha-glucosidase inhibitor
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US20020198201A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an aldose reductase inhibitor
US6734197B2 (en) 2001-06-07 2004-05-11 Wyeth Combination therapy for type II diabetes or Syndrome X
WO2002098414A1 (en) * 2001-06-07 2002-12-12 Wyeth Methods using ptpase inhibitors and insulin
US20020198202A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an antilipemic agent
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
JP2005508355A (ja) * 2001-10-19 2005-03-31 トランス　テック　ファーマ，インコーポレイテッド 治療薬としてのビス−ヘテロアリールアルカン
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
AU2002349705A1 (en) 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
ITMI20022172A1 (it) * 2002-10-14 2004-04-15 Clariant Lsm Italia Spa Processo per la preparazione di 3-alchil-tiofeni-2, 5-disostituiti.
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
CA2509222A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1726190A (zh) 2002-12-10 2006-01-25 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－羰基－1h－吲哚－1－基乙酸衍生物
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
ATE411288T1 (de) 2002-12-10 2008-10-15 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
US7718377B2 (en) 2003-05-29 2010-05-18 Kyoto Pharmaceutical Industries, Ltd. Insulin resistance curative and method of screening the same
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
FR2862645B1 (fr) * 2003-11-20 2007-06-22 Merck Sante Sas Composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
MX2007002177A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de pirrolo-naftilo como inhibidores de pai-1.
WO2006023866A2 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
MX2008002117A (es) 2005-08-17 2008-09-26 Wyeth Corp Indoles sustituidos y metodos de uso de estos.
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
GB0822486D0 (en) * 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
CN106749169B (zh) * 2016-11-07 2020-04-21 浙江工业大学 一种Ertiprotafib的手性制备方法
CN107033122B (zh) * 2017-05-19 2019-06-14 南方医科大学 一种n-芳基-2-噻吩酰胺类衍生物及其制备方法和用途
WO2019208713A1 (ja) 2018-04-26 2019-10-31 国立大学法人東京工業大学 多能性幹細胞の分化促進方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505846A (fr) * 1968-08-15 1971-04-15 Parke Davis & Co Procédé de préparation de nouveaux composés hétérocycliques
US3639422A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 4-phenylindole-1 (and 7)-acetic acids
US3682976A (en) * 1970-02-16 1972-08-08 Parke Davis & Co Phenyl benzofuran acetic acid compounds
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
FR2599740B1 (fr) * 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
JPH01135766A (ja) * 1987-11-20 1989-05-29 Tanabe Seiyaku Co Ltd ビフェニル誘導体
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone

Also Published As

Publication number Publication date
IL139132A0 (en) 2001-11-25
TR200003333T2 (tr) 2001-02-21
JP2002516321A (ja) 2002-06-04
AU756337B2 (en) 2003-01-09
BG104918A (bg) 2001-08-31
HUP0101792A2 (hu) 2002-01-28
TW510900B (en) 2002-11-21
NO20005677D0 (no) 2000-11-10
EE200000653A (et) 2002-04-15
HRP20000767A2 (en) 2001-10-31
PL344081A1 (en) 2001-09-24
ZA200005961B (en) 2001-10-24
EP1077969A1 (en) 2001-02-28
CA2330620A1 (en) 1999-12-02
SK16992000A3 (sk) 2001-04-09
EA200001175A1 (ru) 2001-06-25
NO20005677L (no) 2000-12-05
AU3893999A (en) 1999-12-13
KR20010043539A (ko) 2001-05-25
WO1999061435A1 (en) 1999-12-02
HUP0101792A3 (en) 2003-01-28
AR015294A1 (es) 2001-04-18
ID26244A (id) 2000-12-07
CN1308626A (zh) 2001-08-15

Similar Documents

Publication Publication Date Title
BR9911779A (pt) Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia
BR0013667A (pt) Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0214967A (pt) Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
BR9915701A (pt) Composto, droga contendo um composto, e, uso de um composto
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0009864A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
BR9916279A (pt) Composto, composição farmacêutica, uso de um composto, métodos de tratar ou prevenir doenças do sistema endocrinológico e diabetes melittus não dependente de insulina em um paciente em necessidade deste, e de tratar glicose de resistência prejudicada (ifg) ou tolerância à glicose prejudica (igt) em um paciente em necessida deste, processo para a fabricação de um medicamento particular a ser usado no tratamento ou prevenção de doenças do sistema endocrinológico, e, métodos para preparar os compostos
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR0112476A (pt) Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia
RU94044454A (ru) Ингибитор аутоимунных заболеваний
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
DK0658110T3 (da) Anvendelse af norastemizol til behandling af allergisk rhinitis
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
NZ516290A (en) Substituted phenoxyacetic acids
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
BR9813549A (pt) Processo para prevenção e tratamento de miocárdio afetado por lesão
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
BR0113461A (pt) Compostos ou sais farmaceuticamente aceitáveis, composições farmacêuticas, método de tratamento de doença ou condição mediada por erab, hadh2 ou (beta)-amilóide em mamìferos, métodos de inibição ou modulação da atividade enzimática de erab ou hadh2 e método de tratamento de mal de alzheimer ou demência em mamìferos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.